9Gupta R, Thami GP. Fixed drug eruption caused by itraconazole: Reactivity and cross reactivity [ J ]. J Am Acad Dermatol, 2008, 58 (3): 521-522.
10Garcia Rodriguez LA,Duque A,Castellsague J,et al.A cohort study on the risk of acute liver injury among users of keteconazole and other antifungal dross[J].Br J Clin Pharmacol,1999,48(6):847-852.
3Kim JH, Jin H J, Nam YH, et al. Clinical features of allergic bronchopulmonary aspergillosis in Korea[J]. Allergy Asthma Immunol Res, 2012, 4(5): 305-308.
4Mahdavinia M, Grammer LC. Management of allergic bronchopulmonary aspergillosis: a review and update[J]. Ther Adv Respir Dis, 2012, 6(3): 173-187.
5Agarwal R, Khan A, Aggarwal AN, et al. Role of inhaled eorticosteroids in the management of serological allergic bronchopulmonary aspergilosis (ABPA)[J]. Intern Med, 2011, 50(8): 855-860.
6桑福德.抗微生物治疗指南[M].41版.北京:中国协和医科大学出版社,2011:115.
7De Beule K, Van Gestel J. Pharmacology of itraconazole[J]. Drugs, 2001, 61(Suppl 1): S27-S37.